Abstract 528P
Background
To compare the effects of high biologically effective dose (BED) and low BED radiotherapy for small cell lung cancer (SCLC) with brain metastases (BMs), and identify the prognostic factors of survival.
Methods
A total of 250 consecutive limited-stage (LC) SCLC with BMs patients in our institution were retrospectively analyzed, from January 1998 to June 2018. Preliminary screening of the prognostic factors was accomplished by Kaplan-Meier univariate analysis. Baseline covariates were balanced by a propensity-matching analysis. And survival curves between two groups were compared by log-rank test. The Cox regression model was used to analyze factors associated with prognosis.
Results
The Cutoff Finder program exported an optimal BED cutoff value of 47 for all patients. The high-BED (>47 Gy) group had a significantly better brain metastases progression-free survival (BMPFS) than low-BED (≤47 Gy) group (median BMPFS: 14.4 vs. 8.3, P < 0.001). Multivariate analysis found that BED, smoking and age (P < 0.001) were independently prognostic factors affecting BMPFS. And after 1:2 propensity score matching, 176 patients were divided into the high-BED group (n = 59) and the low-BED group (n = 117). In the matched cohort, BMPFS was significantly higher in the high-BED group than low-BED group (P < 0.001).
Conclusions
BED, smoking and age were observed to affect BMPFS of SCLC patients with BMs. High BED radiotherapy (>47 Gy) might improve local control. Additional study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract